Wednesday, November 19, 2025 at 2-3pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Migraine is a complex, chronic disease that results in significant patient and economic burden. Migraine ranks second worldwide in terms of years lost due to disability. Direct annual all cause healthcare costs for a migraine patient are over twice that of a non-migraine patient. Indirect costs from the impact of the disease on a patient’s ability to function (absenteeism and presenteeism) total over $35B annually.

Given this impact , one of the primary goals of acute treatment of migraine is rapid and consistent freedom from pain and associated symptoms without recurrence. Regardless of migraine frequency or time of month, it is important that every appropriate person with migraine be offered a migraine-specific treatment.

Notably, over 50% of females with migraine disease experience migraine attacks during the perimenstrual period, which can be more severe, and longer-lasting than those occurring at other times of the month.

The objective for this webinar is to review the migraine disease state and outline the clinical data for an acute treatment of migraine including data for perimenstrual attacks.

Learning Objectives

• Discuss the complexity of migraine disease and the burden of the disease as it relates to function.
• Discuss an acute treatment option for migraine in adults.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.